QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 this-lululemon-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 this-biogen-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Core News & Articles

Leerink Partners analyst Faisal Khurshid initiates coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Outperform ratin...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and raises the price ta...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Core News & Articles

Contineum Therapeutics, Inc.

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and lowers the price ta...

Core News & Articles

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and maintains $31 price...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Core News & Articles

Jones Trading analyst Debanjana Chatterjee initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Buy rating and ...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung assumes Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and maintains Pric...

Core News & Articles

Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from ...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate...

Core News & Articles

- Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity- Topline data readout planned for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION